[New pharmaceuticals in systemic mycoses (author's transl)].
The chemotherapy of systemic fungal infections remains problematic due to a lack of alternative agents. There are only 3 drugs available: Amphotericin B, 5-Fluorcytosine and the new iv.-formulation of Miconazole. There are as yet limited experiences concerning one of the Imidazole-derivatives of the new generation, Ketoconazole. The main antimycotic and pharmacokinetic properties of these drugs will be discussed.
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008825:Miconazole / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents; D007093:Imidazoles; C029899:imidazole; D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine
Neue Antimykotika für System-Mykosen.